Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the 12.4% return of the Russell 2000 Index ETF (IWM) and the 12.5% return for the Russell 2000 Value Index ETF (IWN). Year-to-date, the fund is up 4.9% net compared to 10.3% and 8.9% returns for the indexes, respectively. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2025.

In its third-quarter 2025 investor letter, Summers Value Partners highlighted stocks such as UniQure N.V. (NASDAQ:QURE). UniQure N.V. (NASDAQ:QURE) is a biotechnology company that engages in the development of treatments for patients suffering from rare and other devastating diseases. The one-month return of UniQure N.V. (NASDAQ:QURE) was -50.41%, and its shares gained 421.23% of their value over the last 52 weeks. On November 18, 2025, UniQure N.V. (NASDAQ:QURE) stock closed at $29.71 per share, with a market capitalization of $1.851 billion.

Summers Value Partners stated the following regarding UniQure N.V. (NASDAQ:QURE) in its third quarter 2025 investor letter:

“The Fund held twelve long positions and no shorts at quarter-end. We initiated a position in UniQure N.V. (NASDAQ:QURE) following encouraging Phase 3 results for its gene therapy drug in Huntington’s Disease, which showed a 75% reduction in disease progression – a game-changing outcome in a field that has been devoid of clinical progress. Given the early stage of development, we have sized the position appropriately. “

Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?

UniQure N.V. (NASDAQ:QURE) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 36 hedge fund portfolios held UniQure N.V. (NASDAQ:QURE) at the end of the second quarter, up from 35 in the previous quarter. In the September quarter, UniQure N.V. (NASDAQ:QURE) reported $3.7 million in revenue compared to $2.3 million in Q3 2024. While we acknowledge the risk and potential of UniQure N.V. (NASDAQ:QURE) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UniQure N.V. (NASDAQ:QURE) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered UniQure N.V. (NASDAQ:QURE) and shared the list of hottest small cap stocks to buy. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.